Advances in molecular imaging of pancreatic beta cells

Mai Lin, Angelo Lubag, Michael J. McGuire, Serguei Y. Seliounine, Edward N. Tsyganov, Peter P. Antich, A. Dean Sherry, Kathlynn C. Brown, Xiankai Sun

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The development of non-invasive imaging methods for early diagnosis of beta cell associated metabolic diseases, including type 1 and type 2 diabetes (T1D and T2D), has recently drawn interest from the molecular imaging community and clinical investigators. Due to the challenges imposed by the location of the pancreas, the sparsely dispersed beta cell population within the pancreas, and the poor understanding of the pathogenesis of the diseases, clinical diagnosis of beta cell abnormalities is still limited. Current diagnostic methods are invasive, often inaccurate, and usually performed post-onset of the disease. Advances in imaging techniques for probing beta cell mass and function are needed to address this critical health care problem. A variety of imaging techniques have been tested for the assessment of pancreatic beta cell islets. Here we discuss current advances in magnetic resonance imaging (MRI), bioluminescence imaging (BLI), and nuclear imaging for the study of beta cell diseases. Spurred by early successes in nuclear imaging techniques for beta cells, especially positron emission tomography (PET), the need for beta cell specific ligands has expanded. Progress for obtaining such ligands is presented. We report our preliminary efforts of developing such a peptidic ligand for PET imaging of pancreatic beta cells.

Original languageEnglish (US)
Pages (from-to)4558-4575
Number of pages18
JournalFrontiers in Bioscience
Volume13
Issue number12
DOIs
StatePublished - 2008

Fingerprint

Molecular imaging
Molecular Imaging
Insulin-Secreting Cells
Imaging techniques
Positron emission tomography
Ligands
Positron-Emission Tomography
Pancreas
Bioluminescence
Metabolic Diseases
Critical Care
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Magnetic resonance
Medical problems
Health care
Early Diagnosis
Research Personnel
Magnetic Resonance Imaging
Delivery of Health Care

Keywords

  • Beta cell
  • Bioluminescence imaging
  • BLI
  • Diabetes
  • Magnetic resonance imaging
  • Molecular imaging
  • MRI
  • Nuclear imaging
  • PET
  • Positron emission tomography
  • Single photon emission tomography
  • SPECT

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Lin, M., Lubag, A., McGuire, M. J., Seliounine, S. Y., Tsyganov, E. N., Antich, P. P., ... Sun, X. (2008). Advances in molecular imaging of pancreatic beta cells. Frontiers in Bioscience, 13(12), 4558-4575. https://doi.org/10.2741/3023

Advances in molecular imaging of pancreatic beta cells. / Lin, Mai; Lubag, Angelo; McGuire, Michael J.; Seliounine, Serguei Y.; Tsyganov, Edward N.; Antich, Peter P.; Sherry, A. Dean; Brown, Kathlynn C.; Sun, Xiankai.

In: Frontiers in Bioscience, Vol. 13, No. 12, 2008, p. 4558-4575.

Research output: Contribution to journalArticle

Lin, M, Lubag, A, McGuire, MJ, Seliounine, SY, Tsyganov, EN, Antich, PP, Sherry, AD, Brown, KC & Sun, X 2008, 'Advances in molecular imaging of pancreatic beta cells', Frontiers in Bioscience, vol. 13, no. 12, pp. 4558-4575. https://doi.org/10.2741/3023
Lin M, Lubag A, McGuire MJ, Seliounine SY, Tsyganov EN, Antich PP et al. Advances in molecular imaging of pancreatic beta cells. Frontiers in Bioscience. 2008;13(12):4558-4575. https://doi.org/10.2741/3023
Lin, Mai ; Lubag, Angelo ; McGuire, Michael J. ; Seliounine, Serguei Y. ; Tsyganov, Edward N. ; Antich, Peter P. ; Sherry, A. Dean ; Brown, Kathlynn C. ; Sun, Xiankai. / Advances in molecular imaging of pancreatic beta cells. In: Frontiers in Bioscience. 2008 ; Vol. 13, No. 12. pp. 4558-4575.
@article{c170a1fdbf534f358526378acb8a5d43,
title = "Advances in molecular imaging of pancreatic beta cells",
abstract = "The development of non-invasive imaging methods for early diagnosis of beta cell associated metabolic diseases, including type 1 and type 2 diabetes (T1D and T2D), has recently drawn interest from the molecular imaging community and clinical investigators. Due to the challenges imposed by the location of the pancreas, the sparsely dispersed beta cell population within the pancreas, and the poor understanding of the pathogenesis of the diseases, clinical diagnosis of beta cell abnormalities is still limited. Current diagnostic methods are invasive, often inaccurate, and usually performed post-onset of the disease. Advances in imaging techniques for probing beta cell mass and function are needed to address this critical health care problem. A variety of imaging techniques have been tested for the assessment of pancreatic beta cell islets. Here we discuss current advances in magnetic resonance imaging (MRI), bioluminescence imaging (BLI), and nuclear imaging for the study of beta cell diseases. Spurred by early successes in nuclear imaging techniques for beta cells, especially positron emission tomography (PET), the need for beta cell specific ligands has expanded. Progress for obtaining such ligands is presented. We report our preliminary efforts of developing such a peptidic ligand for PET imaging of pancreatic beta cells.",
keywords = "Beta cell, Bioluminescence imaging, BLI, Diabetes, Magnetic resonance imaging, Molecular imaging, MRI, Nuclear imaging, PET, Positron emission tomography, Single photon emission tomography, SPECT",
author = "Mai Lin and Angelo Lubag and McGuire, {Michael J.} and Seliounine, {Serguei Y.} and Tsyganov, {Edward N.} and Antich, {Peter P.} and Sherry, {A. Dean} and Brown, {Kathlynn C.} and Xiankai Sun",
year = "2008",
doi = "10.2741/3023",
language = "English (US)",
volume = "13",
pages = "4558--4575",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "12",

}

TY - JOUR

T1 - Advances in molecular imaging of pancreatic beta cells

AU - Lin, Mai

AU - Lubag, Angelo

AU - McGuire, Michael J.

AU - Seliounine, Serguei Y.

AU - Tsyganov, Edward N.

AU - Antich, Peter P.

AU - Sherry, A. Dean

AU - Brown, Kathlynn C.

AU - Sun, Xiankai

PY - 2008

Y1 - 2008

N2 - The development of non-invasive imaging methods for early diagnosis of beta cell associated metabolic diseases, including type 1 and type 2 diabetes (T1D and T2D), has recently drawn interest from the molecular imaging community and clinical investigators. Due to the challenges imposed by the location of the pancreas, the sparsely dispersed beta cell population within the pancreas, and the poor understanding of the pathogenesis of the diseases, clinical diagnosis of beta cell abnormalities is still limited. Current diagnostic methods are invasive, often inaccurate, and usually performed post-onset of the disease. Advances in imaging techniques for probing beta cell mass and function are needed to address this critical health care problem. A variety of imaging techniques have been tested for the assessment of pancreatic beta cell islets. Here we discuss current advances in magnetic resonance imaging (MRI), bioluminescence imaging (BLI), and nuclear imaging for the study of beta cell diseases. Spurred by early successes in nuclear imaging techniques for beta cells, especially positron emission tomography (PET), the need for beta cell specific ligands has expanded. Progress for obtaining such ligands is presented. We report our preliminary efforts of developing such a peptidic ligand for PET imaging of pancreatic beta cells.

AB - The development of non-invasive imaging methods for early diagnosis of beta cell associated metabolic diseases, including type 1 and type 2 diabetes (T1D and T2D), has recently drawn interest from the molecular imaging community and clinical investigators. Due to the challenges imposed by the location of the pancreas, the sparsely dispersed beta cell population within the pancreas, and the poor understanding of the pathogenesis of the diseases, clinical diagnosis of beta cell abnormalities is still limited. Current diagnostic methods are invasive, often inaccurate, and usually performed post-onset of the disease. Advances in imaging techniques for probing beta cell mass and function are needed to address this critical health care problem. A variety of imaging techniques have been tested for the assessment of pancreatic beta cell islets. Here we discuss current advances in magnetic resonance imaging (MRI), bioluminescence imaging (BLI), and nuclear imaging for the study of beta cell diseases. Spurred by early successes in nuclear imaging techniques for beta cells, especially positron emission tomography (PET), the need for beta cell specific ligands has expanded. Progress for obtaining such ligands is presented. We report our preliminary efforts of developing such a peptidic ligand for PET imaging of pancreatic beta cells.

KW - Beta cell

KW - Bioluminescence imaging

KW - BLI

KW - Diabetes

KW - Magnetic resonance imaging

KW - Molecular imaging

KW - MRI

KW - Nuclear imaging

KW - PET

KW - Positron emission tomography

KW - Single photon emission tomography

KW - SPECT

UR - http://www.scopus.com/inward/record.url?scp=42549163253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549163253&partnerID=8YFLogxK

U2 - 10.2741/3023

DO - 10.2741/3023

M3 - Article

VL - 13

SP - 4558

EP - 4575

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 12

ER -